imiquimod has been researched along with tacrolimus in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 8 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Arndt, KA; Dover, JS; Lipper, GM | 1 |
| Hengge, UR; Meykadeh, N | 1 |
| Berman, B; Poochareon, VN | 1 |
| Sidbury, R | 1 |
| Skinner, R | 1 |
| Sauder, DN | 1 |
| Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W | 1 |
| Choi, EH; Hong, SP; Jung, M; Jung, YJ; Kim, M | 1 |
| Aber, C; Kirsner, RS | 1 |
| Haddad, E; Hatami, A; Marcoux, D; McCuaig, CC; Piram, M; Powell, J; Saint-Cyr, C | 1 |
| Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH | 1 |
| Courthion, H; Denis, MC; Gabriel, D; Gurny, R; Kalia, Y; Karagianni, N; Kranidioti, K; Lapteva, M; Möller, M; Mugnier, T | 1 |
| Domb, AJ; Doppalapudi, S; Jain, A; Khan, W | 1 |
| Fluhr, JW; Gruber, AD; Hedtrich, S; Hönzke, S; Kleuser, B; Mundhenk, L; Ostrowski, A; Pischon, H; Radbruch, M; Schumacher, F | 1 |
| Fujita, T; Hamano, I; Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Murakami, R; Narumi, S; Ohyama, C; Saitoh, H; Shimada, M; Suzuki, T; Tomita, H; Yamamoto, H; Yoneyama, T | 1 |
| Bentley, MVLB; Caron, AL; Del Ciampo, JO; Kravicz, M; Medina, WSG; Praça, FG; Silvestrini, AVP; Suzuki, I; Viegas, JSR | 1 |
| Choo, YK; Jang, WG; Jeon, SH; Kim, CH; Lee, JH; Park, JH; Park, MY | 1 |
| Fukumoto, T; Furuoka, K; Nagai, H; Nishigori, C | 1 |
| Abdel-Mottaleb, MMA; Arafa, MG; El-Zaafarany, GM; Fereig, SA | 1 |
| Gu, J; Shi, Y; Wang, H; Yao, L; Yu, Q; Zhang, X; Zhao, Z | 1 |
| Cheng, G; Jin, S; Liu, W; Mi, R; Pan, W; Piao, H; Zou, M | 1 |
| Dadwal, N; Singh, A; Singh, D | 1 |
4 review(s) available for imiquimod and tacrolimus
| Article | Year |
|---|---|
New therapies for the management of keloids.
Topics: Adrenal Cortex Hormones; Aminoquinolines; Chemotherapy, Adjuvant; Humans; Imiquimod; Immunosuppressive Agents; Interferon alpha-2; Interferon Inducers; Interferon-alpha; Keloid; Laser Therapy; Recombinant Proteins; Tacrolimus | 2003 |
What's new in pediatric dermatology: update for the pediatrician.
Topics: Adjuvants, Immunologic; Aminoquinolines; Child; Clinical Trials as Topic; Dermatitis, Atopic; Hemangioma; Humans; Imiquimod; Immunoglobulins; Immunologic Factors; Immunosuppressive Agents; Infant; Molluscum Contagiosum; Skin; Skin Diseases; Stevens-Johnson Syndrome; Tacrolimus; Vitiligo; Warts | 2004 |
Role of topical therapies in the management of cutaneous disease.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Condylomata Acuminata; Dermatitis, Atopic; Dermatitis, Seborrheic; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis; Melanoma; Membrane Glycoproteins; Receptors, Cell Surface; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Toll-Like Receptors | 2004 |
Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions.
Topics: Adjuvants, Immunologic; Alefacept; Aminoquinolines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcineurin Inhibitors; CD11 Antigens; Dermatitis, Atopic; Glucocorticoids; Humans; Imiquimod; Interferons; Membrane Glycoproteins; Mycophenolic Acid; Psoriasis; Receptors, Cell Surface; Recombinant Fusion Proteins; Skin Diseases; Tacrolimus; Toll-Like Receptors | 2004 |
20 other study(ies) available for imiquimod and tacrolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Recent therapeutic advances in dermatology.
Topics: Adjuvants, Immunologic; Aminoquinolines; Condylomata Acuminata; Dermatitis; Dermatology; Humans; Imiquimod; Interferon Inducers; Keratolytic Agents; Stevens-Johnson Syndrome; Tacrolimus | 2000 |
[Topical immunomodulators in dermatology].
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Asthma; Autoimmune Diseases; Bowen's Disease; Child; Cyclopropanes; Dermatitis, Atopic; Dinitrochlorobenzene; Female; Follow-Up Studies; Herpes Simplex; Humans; Imidazoles; Imiquimod; Immunity, Cellular; Immunocompromised Host; Immunoglobulin A; Immunosuppressive Agents; Lichen Sclerosus et Atrophicus; Male; Molluscum Contagiosum; Papillomavirus Infections; Precancerous Conditions; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Time Factors; Warts | 2003 |
Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Topics: Adult; Aged; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Imiquimod; Immunosuppressive Agents; Interferons; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prednisone; PUVA Therapy; Remission Induction; Skin; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Time Factors; Treatment Outcome; Vincristine | 2003 |
IL-1α stimulation restores epidermal permeability and antimicrobial barriers compromised by topical tacrolimus.
Topics: Administration, Topical; Adult; Aminoquinolines; Animals; Antimicrobial Cationic Peptides; beta-Defensins; Cathelicidins; Cell Membrane; Cell Membrane Permeability; Desmosomes; Epidermal Cells; Epidermis; Female; Humans; Imiquimod; Immunosuppressive Agents; Interleukin-1alpha; Lipid Metabolism; Male; Mice; Mice, Hairless; Mice, Knockout; Middle Aged; Models, Animal; Receptors, Interleukin-1; Tacrolimus | 2011 |
Restoring tacrolimus-induced impaired barrier function.
Topics: Aminoquinolines; Animals; Antimicrobial Cationic Peptides; beta-Defensins; Cathelicidins; Cell Membrane; Cell Membrane Permeability; Dermatitis, Atopic; Epidermal Cells; Epidermis; Humans; Imiquimod; Immunosuppressive Agents; Interleukin-1alpha; Lipid Metabolism; Mice; Mice, Transgenic; Models, Animal; Receptors, Interleukin-1; Signal Transduction; Tacrolimus | 2011 |
Short- and long-term outcome of linear morphoea in children.
Topics: Adolescent; Adrenal Cortex Hormones; Age of Onset; Aminoquinolines; Calcitriol; Child; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Imiquimod; Male; Methotrexate; Ointments; Phototherapy; Retrospective Studies; Scleroderma, Localized; Tacrolimus; Treatment Outcome; Vitamin A; Vitamin E | 2013 |
Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs.
Topics: Aminolevulinic Acid; Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Female; Imiquimod; Mice; Psoriasis; Skin; Skin Absorption; Tacrolimus; Tretinoin | 2015 |
Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Biological Availability; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Hydrogels; Imiquimod; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Polymers; Psoriasis; Skin; Skin Absorption; Solubility; Tacrolimus | 2016 |
Tacrolimus and curcumin co-loaded liposphere gel: Synergistic combination towards management of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Chemistry, Pharmaceutical; Curcumin; Delayed-Action Preparations; Dermatologic Agents; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gels; Imiquimod; Immunosuppressive Agents; Lipids; Male; Mice; Mice, Inbred BALB C; Particle Size; Psoriasis; Tacrolimus; Tissue Distribution | 2016 |
How Effective Is Tacrolimus in the Imiquimod-Induced Mouse Model of Psoriasis?
Topics: Administration, Cutaneous; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imiquimod; Immunosuppressive Agents; Male; Mice; Mice, Hairless; Mice, Inbred BALB C; Psoriasis; Skin; Tacrolimus; Treatment Outcome | 2018 |
Condyloma Acuminata of the Urethra in a Male Renal Transplant Recipient: A Case Report.
Topics: Adult; Condylomata Acuminata; Everolimus; Humans; Imiquimod; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Male; Tacrolimus; Transplant Recipients; Urethral Diseases | 2018 |
Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis.
Topics: Administration, Cutaneous; Animals; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Synergism; Female; Imiquimod; Liposomes; Male; Mice; Mice, Inbred BALB C; Nanoparticles; NIH 3T3 Cells; Particle Size; Psoriasis; RNA, Small Interfering; Tacrolimus; Tumor Necrosis Factor-alpha | 2020 |
Therapeutic anti-psoriatic effects of myeloid-derived suppressor cells in combination with systemic tacrolimus (FK-506) in an imiquimod-induced mouse model of psoriasis.
Topics: Animals; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Immunomodulation; Immunosuppressive Agents; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Psoriasis; Skin; Spleen; T-Lymphocytes, Regulatory; Tacrolimus; Th1 Cells; Th17 Cells | 2020 |
Topical imiquimod-induced lichenoid drug reaction successfully treated with tacrolimus ointment.
Topics: Administration, Topical; Humans; Imiquimod; Immunosuppressive Agents; Ointments; Tacrolimus; Treatment Outcome | 2020 |
Tacrolimus-loaded chitosan nanoparticles for enhanced skin deposition and management of plaque psoriasis.
Topics: Administration, Cutaneous; Animals; Chitosan; Drug Carriers; Drug Liberation; Ear; Imiquimod; Immunosuppressive Agents; Mice, Inbred C57BL; Nanoparticles; Particle Size; Psoriasis; Rats, Sprague-Dawley; Skin; Tacrolimus | 2021 |
Efficient local delivery of FK506 using blocking patches in psoriasis.
Topics: Administration, Cutaneous; Animals; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Tacrolimus | 2023 |
Tacrolimus and paclitaxel co-loaded O/O ointment without surfactant: Synergistic combinations for the treatment of psoriasis.
Topics: Humans; Imiquimod; Ointments; Paclitaxel; Psoriasis; Pulmonary Surfactants; Surface-Active Agents; Tacrolimus | 2023 |
Quality-by-Design Approach for Investigating the Efficacy of Tacrolimus and Hyaluronic Acid-Loaded Ethosomal Gel in Dermal Management of Psoriasis: In Vitro, Ex Vivo, and In Vivo Evaluation.
Topics: Administration, Cutaneous; Humans; Hyaluronic Acid; Imiquimod; Psoriasis; Skin; Tacrolimus | 2023 |